sb-277011 and naxagolide

sb-277011 has been researched along with naxagolide* in 2 studies

Other Studies

2 other study(ies) available for sb-277011 and naxagolide

ArticleYear
Low dose pramipexole causes D3 receptor-independent reduction of locomotion and responding for a conditioned reinforcer.
    Neuropharmacology, 2015, Volume: 89

    Pramipexole is a clinically important dopamine receptor agonist with reported selectivity for dopamine D3 receptors over other dopaminergic and non-dopaminergic sites. Many of its behavioural effects are therefore attributed to D3 receptor activity. Here we relate pramipexole's ex vivo D2 and D3 receptor binding (measured using [(3)H]-(+)-PHNO binding experiments) to its effects on locomotion and operant responding for primary and conditioned reinforcers. We show that pramipexole has inhibitory behavioural effects on all three behaviours at doses that occupy D3 but not D2 receptor. However, these effects are 1) not inhibited by a D3 selective dose of the antagonist SB-277011-A, and 2) present in D3 receptor knockout mice. These results suggest that a pharmacological mechanism other than D3 receptor activity must be responsible for these behavioural effects. Finally, our receptor binding results also suggest that these behavioural effects are independent of D2 receptor activity. However, firmer conclusions regarding D2 involvement would be aided by further pharmacological or receptor knock-out experiments. The implications of our findings for the understanding of pramipexole's behavioural and clinical effects are discussed.

    Topics: Animals; Benzothiazoles; Brain; Conditioning, Operant; Dopamine Agonists; Dose-Response Relationship, Drug; Locomotion; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitriles; Oxazines; Pramipexole; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Dopamine D3; Reinforcement, Psychology; Tetrahydroisoquinolines; Tritium

2015
In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice.
    Synapse (New York, N.Y.), 2009, Volume: 63, Issue:9

    Examination of dopamine-D3 (D3) receptors with positron emission tomography (PET) have been hampered in the past by the lack of a PET ligand with sufficient selectivity for D3 over dopamine-D2 (D2) receptors. The two types co-localize in the brain, with D2 density significantly higher than D3, hence nonselective PET ligands inform on D2, rather than D3 status. [(11)C]-(+)-PHNO is a novel PET ligand with a preferential affinity for D3 over D2. We used the selective D3 antagonist, SB-277011 to dissect regional fractions of the [(11)C]-(+)-PHNO signal attributable to D3 and D2 in primate brain. The results were compared with quantitative autoradiography with (3)H-(+)-PHNO in wild-type, D2-knock-out, and D3-knock-out mice examined at baseline and following administration of SB-277011. Both sets of results converged to indicate a predominant D3-related component to (+)-PHNO binding in extra-striatal regions, with binding in the midbrain being entirely attributable to D3. The midbrain is thus an excellent target region to examine D3 receptor occupancy with [(11)C]-(+)-PHNO PET in vivo.

    Topics: Animals; Binding, Competitive; Brain; Dopamine; Dopamine Agonists; Dopamine Antagonists; Mesencephalon; Mice; Mice, Knockout; Nitriles; Oxazines; Papio anubis; Positron-Emission Tomography; Receptors, Dopamine D2; Receptors, Dopamine D3; Tetrahydroisoquinolines

2009